Cullgen Revenue and Competitors

Location

$116M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cullgen's estimated annual revenue is currently $2.7M per year.(i)
  • Cullgen's estimated revenue per employee is $77,500
  • Cullgen's total funding is $116M.

Employee Data

  • Cullgen has 35 Employees.(i)
  • Cullgen grew their employee count by -8% last year.

Cullgen's People

NameTitleEmail/Phone
1
Chief Scientific OfficerReveal Email/Phone
2
Assistant DirectorReveal Email/Phone
3
Medical DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Cullgen?

Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com

keywords:N/A

$116M

Total Funding

35

Number of Employees

$2.7M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cullgen News

2022-04-13 - GNI : FY2021 Annual General Meeting Q&A Summary

Q3: What is Cullgen's PROTAC drug pipeline and also IPO status? A3: You will start seeing more IND's from Cullgen this year. We expect 2-3 IND's...

2022-04-06 - Global Targeted Protein Degradation (TPD) Market ...

... Casma Therapeutics; Celeris Therapeutics; Centessa Pharmaceuticals; Coho Therapeutics; ComInnex; Cullgen; Cullinan Oncology; Dalriada...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.6M35-15%N/A
#2
$7.6M3552%N/A
#3
$7.1M35-12%N/A
#4
$4.1M35N/AN/A
#5
$3.9M35-36%$2M